{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:02:16Z","timestamp":1788415336328,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00259-024-06718-6","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T03:01:56Z","timestamp":1713409316000},"page":"2784-2793","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Same-day post-therapy imaging with a new generation whole-body digital SPECT\/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"51","author":[{"given":"Hong","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Leonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heying","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina Mari","family":"Aparici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Davidzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Franc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagruti","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin P.","family":"Bergstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice C.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Raza","family":"Khaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-5329","authenticated-orcid":false,"given":"Andrei","family":"Iagaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"6718_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"6718_CR2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804.","journal-title":"Lancet"},{"key":"6718_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333.","journal-title":"Lancet Oncol"},{"key":"6718_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","volume":"80","author":"MS Sadaghiani","year":"2021","unstructured":"Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, et al. A systematic review and Meta-analysis of the effectiveness and toxicities of Lutetium-177-labeled prostate-specific membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-resistant prostate Cancer. Eur Urol. 2021;80:82\u201394.","journal-title":"Eur Urol"},{"key":"6718_CR5","first-page":"1651","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, et al. Novel Framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate Cancer (RECIP 1.0): an International Multicenter Study. J Nucl Med. 2022;63:1651\u20138.","journal-title":"J Nucl Med"},{"key":"6718_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","volume":"48","author":"S Fanti","year":"2021","unstructured":"Fanti S, Goffin K, Hadaschik BA, Herrmann K, Maurer T, MacLennan S, et al. Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:469\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6718_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, et al. Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115\u201325.","journal-title":"Lancet Oncol"},{"key":"6718_CR8","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23:1389\u201397.","journal-title":"Lancet Oncol"},{"key":"6718_CR9","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","volume":"46","author":"B Grubmuller","year":"2019","unstructured":"Grubmuller B, Senn D, Kramer G, Baltzer P, D\u2019Andrea D, Grubmuller KH, et al. Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1063\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6718_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2967\/jnumed.122.264677","volume":"64","author":"N John","year":"2023","unstructured":"John N, Pathmanandavel S, Crumbaker M, Counter W, Ho B, Yam AO, et al. (177)Lu-PSMA SPECT quantitation at 6 weeks (dose 2) predicts short progression-free survival for patients undergoing (177)Lu-PSMA-I&T Therapy. J Nucl Med. 2023;64:410\u20135.","journal-title":"J Nucl Med"},{"key":"6718_CR11","doi-asserted-by":"crossref","unstructured":"Pathmanandavel S, Crumbaker M, Ho B, Yam AO, Wilson P, Niman R et al. Evaluation of (177)Lu-PSMA SPECT quantitation as a response biomarker within a prospective (177)Lu-PSMA-617 and NOX66 combination trial (LuPIN). J Nucl Med. 2022.","DOI":"10.2967\/jnumed.122.264398"},{"key":"6718_CR12","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, et al. Joint EANM\/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50:2830\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6718_CR13","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.21.02810","volume":"40","author":"A Gupta","year":"2022","unstructured":"Gupta A, Eisenhauer EA, Booth CM. The Time toxicity of Cancer Treatment. J Clin Oncol. 2022;40:1611\u20135.","journal-title":"J Clin Oncol"},{"key":"6718_CR14","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1007\/s00259-023-06176-6","volume":"50","author":"H Song","year":"2023","unstructured":"Song H, Ferri V, Duan H, Aparici CM, Davidzon G, Franc BL, et al. SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT\/CT in the post (177)Lu-DOTATATE and (177)Lu-PSMA617 setting. Eur J Nucl Med Mol Imaging. 2023;50:2250\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6718_CR15","first-page":"1125","volume":"62","author":"Rani","year":"2021","unstructured":"LE ROUZIC GZ, Rani. First performance measurements of a new multi-detector CZT-Based SPECT\/CT system: GE StarGuide. J Nucl Med. 2021;62:1125.","journal-title":"J Nucl Med"},{"key":"6718_CR16","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial Design and objectives for castration-resistant prostate Cancer: updated recommendations from the prostate Cancer clinical trials Working Group 3. J Clin Oncol. 2016;34:1402\u201318.","journal-title":"J Clin Oncol"},{"key":"6718_CR17","doi-asserted-by":"crossref","first-page":"P1619","DOI":"10.2967\/jnumed.123.265509","volume":"64","author":"A Gafita","year":"2023","unstructured":"Gafita A, DJAILEB L, Rauscher I, Fendler W, Hadaschik B, Herrmann K, et al. Practical RECIP: visual assessment of response evaluation Criteria in PSMA-PET\/CT in metastatic castration-resistant prostate cancer. J Nucl Med. 2023;64:P1619\u2013P.","journal-title":"J Nucl Med"},{"key":"6718_CR18","doi-asserted-by":"crossref","unstructured":"Sartor O. Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). ESMO Congress. 2023.","DOI":"10.1016\/j.annonc.2023.10.085"},{"key":"6718_CR19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","volume":"48","author":"R Seifert","year":"2021","unstructured":"Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48:1200\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6718_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2967\/jnumed.122.264398","volume":"64","author":"S Pathmanandavel","year":"2023","unstructured":"Pathmanandavel S, Crumbaker M, Ho B, Yam AO, Wilson P, Niman R, et al. Evaluation of (177)Lu-PSMA-617 SPECT\/CT quantitation as a response Biomarker within a prospective (177)Lu-PSMA-617 and NOX66 combination trial (LuPIN). J Nucl Med. 2023;64:221\u20136.","journal-title":"J Nucl Med"},{"key":"6718_CR21","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00259-023-06536-2","volume":"51","author":"MC Neubauer","year":"2024","unstructured":"Neubauer MC, Nicolas GP, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, et al. Early response monitoring during [(177)Lu]Lu-PSMA I&T therapy with quantitated SPECT\/CT predicts overall survival of mCRPC patients: subgroup analysis of a swiss-wide prospective registry study. Eur J Nucl Med Mol Imaging. 2024;51:1185\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6718_CR22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1053\/j.semnuclmed.2022.01.004","volume":"52","author":"P Ritt","year":"2022","unstructured":"Ritt P. Recent developments in SPECT\/CT. Semin Nucl Med. 2022;52:276\u201385.","journal-title":"Semin Nucl Med"},{"key":"6718_CR23","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"K Sjogreen Gleisner","year":"2022","unstructured":"Sjogreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49:1778\u2013809.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6718_CR24","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2967\/jnumed.122.264594","volume":"64","author":"J Brosch-Lenz","year":"2023","unstructured":"Brosch-Lenz J, Delker A, Volter F, Unterrainer LM, Kaiser L, Bartenstein P, et al. Toward single-time-point image-based dosimetry of (177)Lu-PSMA-617 therapy. J Nucl Med. 2023;64:767\u201374.","journal-title":"J Nucl Med"},{"key":"6718_CR25","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2967\/jnumed.119.233411","volume":"61","author":"PA Jackson","year":"2020","unstructured":"Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation Dosimetry in (177)Lu-PSMA-617 therapy using a single posttreatment SPECT\/CT scan: a novel methodology to Generate Time- and tissue-specific dose factors. J Nucl Med. 2020;61:1030\u20136.","journal-title":"J Nucl Med"},{"key":"6718_CR26","doi-asserted-by":"crossref","unstructured":"Derlin T, Widjaja L, Werner RA, Bengel FM. (177)Lu-PSMA for Extended Treatment of Metastatic Castration-resistant prostate Cancer. J Nucl Med. 2022.","DOI":"10.2967\/jnumed.122.264293"},{"key":"6718_CR27","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00259-023-06119-1","volume":"50","author":"N Mader","year":"2023","unstructured":"Mader N, Nguyen Ngoc C, Kirkgoze B, Baumgarten J, Groener D, Klimek K, et al. Extended therapy with [(177)Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50:1811\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6718_CR28","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.2967\/jnumed.121.262751","volume":"62","author":"RL Wahl","year":"2021","unstructured":"Wahl RL, Sgouros G, Iravani A, Jacene H, Pryma D, Saboury B, et al. Normal-tissue tolerance to Radiopharmaceutical Therapies, the knowns and the unknowns. J Nucl Med. 2021;62:S23\u201335.","journal-title":"J Nucl Med"},{"key":"6718_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate Cancer: correlations between Pretherapeutic Imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60:517\u201323.","journal-title":"J Nucl Med"},{"key":"6718_CR30","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.2967\/jnumed.121.262749","volume":"62","author":"J Capala","year":"2021","unstructured":"Capala J, Graves SA, Scott A, Sgouros G, James SS, Zanzonico P, et al. Dosimetry for Radiopharmaceutical Therapy: current practices and Commercial resources. J Nucl Med. 2021;62:S3\u201311.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06718-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06718-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06718-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T11:03:12Z","timestamp":1720090992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06718-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["6718"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06718-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"21 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in our study were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Stanford University Institutional Review Board approved this retrospective data analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Andrei Iagaru is an Associate Editor at the European Journal of Nuclear Medicine and Molecular Imaging. Hong Song, Maria Isabel Leonio, Valentina Ferri, Heying Duan, Carina Mari Aparici, Guido Davidzon, Benjamin L. Franc, Farshad Moradi, Jagruti Shah, Colin P Bergstrom, Alice C Fan, Sumit Shah, Ali Raza Khaki and Sandy Srinivas declare that they have no conflict of interest or competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Waived by the Stanford University Institutional Review Board for this retrospective data analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}